An unbiased analysis of positron emission tomography data traces long-distance connections between amyloid and tau pathology in the cortex.
Scientists lay out the first combined epigenomic and transcriptional profile of human microglia. The signature is similar to that of mice, but quickly vanishes when cells are placed in a dish.
At the length that triggers disease, expanded nucleotide repeats cause RNAs to clump into semi-solid foci.
Without the C3 protein, microglia calm down and the mice preserve their memories.
A phosphorylated version of the protease ramps up autophagy, promoting degradation of the C-terminal fragment of amyloid precursor protein, the source of Aβ.
Injected α-synuclein fibrils triggered pathology throughout the mouse brain, even in regions not neuroanatomically connected to the injection site. Astrocytes were loaded with inclusions.
Immune cells lacking the receptor fail to respond to injury and aging, resulting in overall poor brain health in mouse models.
Protein Liquid-Liquid Phase Transitions: The Science Is About to Gel Confused about protein liquid-liquid phase transitions? You are not alone. Researchers working in this emerging field gathered in Leuven in early May to make sense of the latest data ...
At a topical meeting in Leuven, Belgium, a coherent picture began to emerge for how these membraneless organelles function in health and disease.
A veteran of the Battle of the Bulge, Terry trained legions of neuropathologists at Einstein and UCSD. He described paired helical filaments and linked synapse loss to cognitive decline.
Over the past 15 years, deaths attributable to Alzheimer’s have risen 55 percent, according to the CDC, and more people are living at home when they die, suggesting a need to support caregivers.
A study of nearly 80,000 individuals unearthed 52 genes tied to general intelligence, 40 of which are new.
Researchers implicate these innate immune cells in the disruption of neurovascular coupling by Aβ in mice.
Tyrosine kinase inhibitors kept diseased motor neurons alive in vitro, and notched positive findings in a recent Phase 3 trial. A new paradigm for ALS treatment?
By targeting distinct cell populations in the external globus pallidus, researchers restore mobility to a mouse model of Parkinson’s disease.